2019 Patient-Centered Provider Relationship 
Annals of Family Medicine
NOVEMBER 20, 2024
Despite efforts to improve patient-clinician relationships, access to care, and healthcare workflows, annual rates of missed appointments (MA) in the U.S Objective To evaluate the association between patient, health system, geosocial, and environmental factors on the likelihood of MA in Family Medicine clinics. for CA, 0.85
Today's Hospitalist
MAY 9, 2025
Since the mid-1990s, our capacity for innovation has never stopped as hospitalists navigate a complex landscape of acute illnesses, interprofessional collaborations and the imperative to provide efficient, high-quality care. Beyond time savings, ambient AI can enhance the quality of our patient interactions. The result?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Clinical Problem Solvers
OCTOBER 18, 2022
Milburn Smith Child Health Research, Outreach, and Advocacy Center at the Ann & Robert H. All healthcare professionals will have patients who are directly or indirectly impacted by the carceral system. People who are incarcerated are dehumanized and feel they are treated as inmates, rather than as patients.
FDA Law Blog
OCTOBER 14, 2021
Mullen — In recent years, for novel robot assisted surgery (RAS) devices, FDA’s Center for Devices and Radiological Health (CDRH) has taken the approach of clearing RAS devices for specific indications for use. These clearances are based on short-term (30 day) patient follow up. By Jeffrey K. Shapiro & Allyson B.
FDA Law Blog
JUNE 23, 2021
Valentine — For the last 13 years, this blogger has been at the center of what has now been dubbed “patient-focused drug development.” For 6 years, I served as a patient liaison within FDA in what was then called the Office of Special Health Issues. By James E. The practice of medicine was viewed as paternalistic.
FDA Law Blog
JANUARY 6, 2022
Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. These lab tests are performed for physicians, substance abuse treatment centers and other types of organizations.
FDA Law Blog
JANUARY 6, 2022
Wasserstein — “EKRA” refers to the Eliminating Kickbacks in Recovery Act, which was part of the Substance Use – Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. These lab tests are performed for physicians, substance abuse treatment centers and other types of organizations.
Expert insights. Personalized for you.
130 
Let's personalize your content